Merck to stop lung condition drug study early due to strong efficacy data
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...
Zacks.com on MSN15h
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
FiercePharma18h
Merck vaccine, Daiichi ADC win approval recommendations in busy week at EU's drug regulator
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Merck & Company Hold Rating: Promising Drug Developments Amid Uncertain Financial Outlook
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...
Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200
We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look ...
FiercePharma1d
With efficacy assured, Merck halts another trial of blockbuster-to-be Winrevair
All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.
Merck, Black Ex-Director Headed for Discriminatory Firing Trial
Merck must face trial on a Black IT director’s claims that racial bias drove his firing after he ordered the removal of a White contractor from a project, a New York federal judge ruled.
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
A Closer Look at Merck & Co's Options Market Dynamics
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...
Hosted on MSN10h
Merck (MRK) Stock Moves -0.13%: What You Should Know
The most recent trading session ended with Merck (MRK) standing at $98.82, reflecting a -0.13% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of 0 ...